daraxonrasib

AXP000027.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS; NRAS; HRAS
Originator
Revolution Medicines
Sponsor
Revolution Medicines

Names

NameTypeSource
daraxonrasibpreferred name, INNcurator, ncit
Rasonquebrandpress
RMC-6236codencit

Cross-references

NCI Thesaurus
C188048
Wikidata
Q136659312
FDA UNII
B6T47Y2UAP

Approvals

No regulatory approval recorded.

Clinical trials (22)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07898813Daraxonrasib in Resectable PDACNot yet recruitingPhase 12027-04-132029-02-1730Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma
NCT07819838Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS MutationsNot yet recruitingPhase 1/22027-04-092032-04-0977Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Neuroblastoma; Recurrent Childhood Rhabdomyosarcoma; Refractory Childhood Malignant Solid Neoplasm; Refractory Childhood Neuroblastoma; Refractory Childhood Rhabdomyosarcoma
NCT07908550Daraxonrasib in Asian RAS-mutant Biliary Tract CancerNot yet recruitingPhase 22027-012029-1255Biliary Tract Cancer (BTC)
NCT07793253Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingPhase 22026-112030-1155Ampulla of Vater Carcinoma; Ampullary Carcinoma; Biliary Tract Cancers; Extrahepatic Cholangiocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma (Icc)
NCT07895498A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic CancerRecruitingPhase 22026-10-162028-10-16122Pancreatic Cancer; Skin Toxicities
NCT07756281First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerRecruitingPhase 12026-09-012029-06-0140Pancreatic Acinar Carcinoma; Pancreatic Cancer
NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 32026-08-282029-03400PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07492680A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 22026-07-272028-08-15254Solid Tumors
NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 32026-03-092028-06900PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/22026-01-302029-05370Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Metastatic Solid Tumors; NSCLC; Non-small Cell Lung Cancer (NSCLC)
NCT07349537Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingPhase 12026-01-082028-04574Advanced Solid Tumors; CRC; Colorectal Cancer (CRC); Lung Cancer (NSCLC); NSCLC; Non-small Cell Lung Cancer (NSCLC); PDAC; Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingPhase 32025-12-152029-05-10500PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Resectable Pancreatic Ductal Adenocarcinoma (PDAC); Resected Pancreatic Adenocarcinoma
NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsRecruitingPhase 1/22025-05-312027-06183Lung Cancer; MTAP Deletion; NSCLC; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; RAS Mutation; Thoracic Cancer
NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingPhase 32025-05-062027-12-01590NSCLC; NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Carcinoma); Non-Small Cell Lung Cancer
NCT06625320Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active not recruitingPhase 32024-10-162026-06500PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer
NCT06360354A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active not recruitingPhase 12024-05-292026-10-31120Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/22024-05-242028-09-301130CRC; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma; PDAC; Pancreatic Ductal Adenocarcinoma
NCT06162221Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/22024-01-182027-06616KRAS G12C-mutated Solid Tumors, Lung Cancer; KRAS, NRAS, HRAS-mutated NSCLC; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; Non-Small Cell Lung Cancer, NSCLC; RAS G12D-mutated NSCLC
NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingPhase 1/22023-11-142028-12534Colorectal Cancer; Non-Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma
NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingPhase 12023-09-072026-12-31604Advanced Solid Tumors; Colorectal Cancer (CRC); Non-small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC)
NCT05379985Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingPhase 1/22022-05-312027-05-31754Advanced Solid Tumors; Colorectal Cancer (CRC); Non-small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07573215Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaApproved for marketingMetastatic Pancreas Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenosquamous Carcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic

Recent changes

SeenTrialChangeDetailTitle
2026-11-12NCT07895498new trialA Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
2026-11-12NCT07898813new trialDaraxonrasib in Resectable PDAC
2026-11-12NCT07908550new trialDaraxonrasib in Asian RAS-mutant Biliary Tract Cancer

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42090791Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.The New England journal of medicine2026cited by trial NCT05379985
PMID 42169926Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report.Journal of gastrointestinal oncology2026name in abstract: RMC-6236
PMID 42223072Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.The New England journal of medicine2026cited by trial NCT06625320
PMID 42244177Dermatologic Toxicities Associated With Novel Pan-RAS/RAF Inhibitors.Journal of cutaneous pathology2026name in abstract: RMC-6236
PMID 42581230Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Nature medicine2026name in title: daraxonrasib
PMID 42685317Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.The New England journal of medicine2026cited by trial NCT05379985
PMID 42827491Multidisciplinary treatment incorporating autologous DC-CIK cell therapy induces long-term survival in advanced pancreatic cancer: a case report.Frontiers in immunology2026name in abstract: daraxonrasib
PMID 42955042Severe Hypercoagulability With Nonbacterial Thrombotic Endocarditis After KRAS Inhibitor Exposure: A Perfect Storm.JACC. Case reports2026name in abstract: daraxonrasib
PMID 40056080Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.Journal of medicinal chemistry2025cited by trial NCT06040541
PMID 40705880A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.Science (New York, N.Y.)2025cited by trial NCT06040541
PMID 38589574Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.Nature2024cited by trial NCT05379985
PMID 38593348Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.Cancer discovery2024cited by trial NCT05379985
PMID 37590355Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.Science (New York, N.Y.)2023cited by trial NCT05379985

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 41186497RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.Cancer immunology research2026name in abstract: daraxonrasib
PMID 41519889Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.Nature communications2026name in abstract: RMC-6236
PMID 41543339RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.Clinical cancer research : an official journal of the American Association for Cancer Research2026name in title: RMC-6236
PMID 41576808Insights into RAS-driven melanoma and its therapeutic implications.Cancer treatment reviews2026name in abstract: daraxonrasib
PMID 41661652The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition.Cancer research2026name in abstract: RMC-6236
PMID 41663526Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.Cancer gene therapy2026name in abstract: RMC-6236
PMID 41670434Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.Cancer discovery2026name in abstract: daraxonrasib
PMID 41756246AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids.Frontiers in pharmacology2026name in abstract: RMC-6236
PMID 41756844Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.bioRxiv : the preprint server for biology2026name in title: daraxonrasib
PMID 41959066Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance.bioRxiv : the preprint server for biology2026name in abstract: RMC-6236
PMID 41969644Acral Lentiginous Melanoma With NRAS Mutation and Ocular Surface Toxicity Following Immunotherapy and Investigational KRASG12C Inhibitor: Case Report.Case reports in oncological medicine2026name in abstract: RMC-6236
PMID 41993359KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.bioRxiv : the preprint server for biology2026name in abstract: RMC-6236
PMID 42030031GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition.Biological chemistry2026name in title: daraxonrasib
PMID 42030930Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma.Cancer cell2026name in abstract: daraxonrasib
PMID 42031346From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Critical reviews in oncology/hematology2026name in abstract: RMC-6236
PMID 42092352Disrupted molecular glue complex drives RAS inhibitor resistance.Cell2026name in abstract: daraxonrasib
PMID 42094384Macrophage-Derived PDGF-BB and GDF-15 Promote Drug Resistance in KRAS-Mutant Colorectal Cancer.bioRxiv : the preprint server for biology2026name in abstract: RMC-6236
PMID 42107507Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue.Pharmacological research2026name in title: daraxonrasib
PMID 42135489Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer.Nature reviews. Clinical oncology2026name in title: daraxonrasib
PMID 42171647Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.Cancer research2026name in abstract: daraxonrasib
PMID 42224594A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Proceedings of the National Academy of Sciences of the United States of America2026name in abstract: daraxonrasib
PMID 42225610Skin health in oncology: evidence-based skin care for cancer patients.The oncologist2026name in abstract: daraxonrasib
PMID 42279426Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.Cancers2026name in abstract: daraxonrasib
PMID 42282555Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236.bioRxiv : the preprint server for biology2026name in title: RMC-6236
PMID 42286127Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma.Nature reviews. Clinical oncology2026name in title: daraxonrasib
PMID 42286311Positive results for daraxonrasib for previously treated metastatic pancreatic cancer.Nature reviews. Gastroenterology & hepatology2026name in title: daraxonrasib
PMID 42372907The potential role of daraxonrasib (RMC-6236) in relapsed neuroblastoma patients and the urgent need for preclinical investigations.Journal of pediatric surgery2026name in title: daraxonrasib
PMID 42393724KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.Journal of hematology & oncology2026name in abstract: RMC-6236
PMID 42398486In Silico identification of natural and synthetic inhibitors targeting KRAS mutants (G12D, G12V, and G12C) and wild-type in pancreatic cancer.Journal of molecular graphics & modelling2026name in abstract: daraxonrasib
PMID 42415848M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.bioRxiv : the preprint server for biology2026name in title: daraxonrasib
PMID 42433800Daraxonrasib in metastatic pancreatic cancer (RASolute 302): survival breakthrough or real-world access barrier?Annals of medicine and surgery (2012)2026name in title: daraxonrasib
PMID 42433811From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial - a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?Annals of medicine and surgery (2012)2026name in title: daraxonrasib
PMID 42436354CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC.The EMBO journal2026name in title: daraxonrasib
PMID 42457978Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein-protein interaction modulators.Acta pharmacologica Sinica2026name in abstract: RMC-6236
PMID 42465401Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic Cancer.bioRxiv : the preprint server for biology2026name in title: daraxonrasib
PMID 42485639Daraxonrasib in Advanced RAS-Mutated Pancreatic Cancer.The New England journal of medicine2026name in title: daraxonrasib
PMID 42485640Daraxonrasib in Advanced RAS-Mutated Pancreatic Cancer. Reply.The New England journal of medicine2026name in title: daraxonrasib
PMID 42523398Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment.bioRxiv : the preprint server for biology2026name in abstract: daraxonrasib
PMID 42551924[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: daraxonrasib
PMID 42551925[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: daraxonrasib
PMID 42557936Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies.Cancer science2026name in title: daraxonrasib
PMID 42562950RAF1 S257L/S259F hotspot mutations: functional characterization and intrinsic resistance to the RAS(ON) inhibitor daraxonrasib in melanoma.Oncogene2026name in title: daraxonrasib
PMID 42567220Daraxonrasib in pancreatic cancer: When progress disrupts practice.Drug discovery today2026name in title: daraxonrasib
PMID 42571010The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.Journal of hematology & oncology2026name in abstract: daraxonrasib
PMID 42580397The Allosteric Revolution: From Static Structures to Conformational Ensembles and Next-Generation Therapeutics.Journal of molecular biology2026name in abstract: daraxonrasib
PMID 42600570Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?Med (New York, N.Y.)2026name in title: daraxonrasib
PMID 42610483Daraxonrasib doubles survival in patients with metastatic pancreatic cancer.Cancer2026name in title: daraxonrasib
PMID 42612796Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology2026name in abstract: daraxonrasib
PMID 42615854Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.Future medicinal chemistry2026name in abstract: RMC-6236
PMID 42617733ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer.Annals of oncology : official journal of the European Society for Medical Oncology2026name in title: daraxonrasib
PMID 42619397Daraxonrasib significantly improves overall and progression-free survival in patients with previously treated metastatic pancreatic cancer.CA: a cancer journal for clinicians2026name in title: daraxonrasib
PMID 42620187A Compact, Standalone & Battery-Powered 3D Organoid-on-Chip System with Programmable Flow Control.bioRxiv : the preprint server for biology2026name in abstract: daraxonrasib
PMID 42620265Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma.bioRxiv : the preprint server for biology2026name in abstract: daraxonrasib
PMID 42645357Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges.Current oncology (Toronto, Ont.)2026name in abstract: daraxonrasib
PMID 42649211Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nature communications2026name in title: daraxonrasib
PMID 42658041Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.Cancer research2026name in title: daraxonrasib
PMID 42663603The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?Future oncology (London, England)2026name in abstract: daraxonrasib
PMID 42667948XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.Cancer letters2026name in abstract: daraxonrasib
PMID 42674713Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells.Anticancer research2026name in title: daraxonrasib
PMID 42678463Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Journal of gastrointestinal cancer2026name in abstract: daraxonrasib
PMID 42679154Discovery and Characterization of RP04340: A Highly Potent and Orally Active Pan-KRAS PROTAC Degrader.Journal of medicinal chemistry2026name in abstract: RMC-6236
PMID 42683315The ERK MAPK pathway in mesenchymal glioblastoma: tumorigenesis, microenvironmental reprogramming, and the therapeutic promise of RAS(ON) multi-selective inhibition.Frontiers in molecular neuroscience2026name in abstract: daraxonrasib
PMID 42689323Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.Cancer discovery2026name in abstract: daraxonrasib
PMID 42691452Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026name in title: daraxonrasib
PMID 42694779Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma.Cureus2026name in title: daraxonrasib
PMID 42705602Equity in expanded access programs for daraxonrasib.Journal of cancer policy2026name in title: daraxonrasib
PMID 42720810Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England)2026name in abstract: RMC-6236
PMID 42731942[In patients with previously treated metastatic pancreatic adenocarcinoma, does daraxonrasib improve overall survival and progression-free survival compared with standard chemotherapy, while being safe?].La Revue de medecine interne2026name in title: daraxonrasib
PMID 42746687ctDNA Profiling Identifies Daraxonrasib Resistance Mechanisms.Cancer discovery2026name in title: daraxonrasib
PMID 42749837Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC.Nature reviews. Clinical oncology2026name in title: daraxonrasib
PMID 42750735RAS-targeted therapies for pancreatic cancer.ESMO gastrointestinal oncology2026name in abstract: daraxonrasib
PMID 42752392Daraxonrasib (Rasonque) for metastatic pancreatic cancer.The Medical letter on drugs and therapeutics2026name in title: daraxonrasib
PMID 42759542Targeting KRAS-Mutant Lung Cancers.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: daraxonrasib
PMID 42776617Current landscape of RAS-targeted therapy for pancreatic cancer.The oncologist2026name in abstract: daraxonrasib
PMID 42778216Daraxonrasib: How soon could the new drug for pancreatic cancer be available in the UK?BMJ (Clinical research ed.)2026name in title: daraxonrasib
PMID 42779967Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition.bioRxiv : the preprint server for biology2026name in title: daraxonrasib
PMID 42797417Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov-Based Narrative Review with a Scoping Approach.Pharmaceuticals (Basel, Switzerland)2026name in abstract: daraxonrasib
PMID 42802048Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma.Drug discoveries & therapeutics2026name in title: daraxonrasib
PMID 42803106Q&A: Eileen O'Reilly on Pancreatic Cancer.Cancer discovery2026name in abstract: daraxonrasib
PMID 42804710Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer.Expert opinion on biological therapy2026name in abstract: daraxonrasib
PMID 42806361Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.Experimental hematology & oncology2026name in title: daraxonrasib
PMID 42814859Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.Cancer research2026name in title: daraxonrasib
PMID 42825474Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor Resistance.Cancer research2026name in abstract: RMC-6236
PMID 42829436Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma.Experimental hematology & oncology2026name in title: RMC-6236
PMID 42836673Targeting RAS in pancreatic cancer.Cancer2026name in abstract: daraxonrasib
PMID 42836735Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.Clinical cancer research : an official journal of the American Association for Cancer Research2026name in abstract: daraxonrasib
PMID 42841489Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.Molecular cancer therapeutics2026name in abstract: daraxonrasib
PMID 42860233Blockade of mutant RAS oncogenic signaling: A 2026 update.Pharmacological research2026name in abstract: daraxonrasib
PMID 42863589Opioid Selection on Daraxonrasib: P-Glycoprotein (P-gp) Blockade and Opioid.Journal of pain and symptom management2026name in title: daraxonrasib
PMID 42869992An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval.Nature reviews. Clinical oncology2026name in title: daraxonrasib
PMID 42870846Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.Translational lung cancer research2026name in abstract: daraxonrasib
PMID 42882807Efficacy and Safety of Daraxonrasib (RMC-6236) in Previously Treated Metastatic RAS-Mutated Pancreatic Ductal Adenocarcinoma: A Systematic Review.Cancers2026name in title: daraxonrasib
PMID 42906096Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer.The New England journal of medicine2026name in title: daraxonrasib
PMID 42906097Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply.The New England journal of medicine2026name in title: daraxonrasib
PMID 42919442Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design.Experimental hematology & oncology2026name in abstract: daraxonrasib
PMID 42946971Development and Validation of an UPLC-QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan-KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies.Biomedical chromatography : BMC2026name in title: daraxonrasib
PMID 42954967The Price of Hope-A Brazilian Oncologist's 4 Encounters With Daraxonrasib.JAMA oncology2026name in title: daraxonrasib
PMID 42956271Efficacy and Safety of KRAS-Targeted Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: An Updated Systematic Review and Meta-Analysis of Pooled Proportions.American journal of clinical oncology2026name in abstract: daraxonrasib
PMID 42956743KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer.Cancer cell2026name in abstract: RMC-6236
PMID 42962509Beyond RAS G12 grouping: testing treatment-specific prediction after daraxonrasib in pancreatic cancer.Cancer treatment and research communications2026name in title: daraxonrasib

NIH grants

ProjectTitleOrganisationPIYearsLinked by
F31CA318096Elucidation and targeting of RAS inhibitor induced metabolic reprogramming for the treatment of pancreatic cancerUNIV OF NORTH CAROLINA CHAPEL HILLACKERMANN, SARAH2026–2026name in abstract: daraxonrasib
R01CA176839Targeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma TherapyUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHMCMAHON, MARTIN2026–2026name in project terms: daraxonrasib
R01CA190394Targeting the cytokine circuitry of KRAS driven lung cancerDANA-FARBER CANCER INSTBARBIE, DAVID A2026–2026name in project terms: daraxonrasib
R01CA300785Adaptation and Evolution of Resistance to Pan-RAS inhibition in PDACCOLUMBIA UNIVERSITY HEALTH SCIENCESOLIVE, KENNETH P.2026–2026name in abstract: RMC-6236
R01CA316420Advancing Pan-RAS Inhibitors for Colorectal Cancer Interception: A Dual Approach Integrating Natural Product Drug Discovery and Preclinical DevelopmentAUBURN UNIVERSITY AT AUBURNPIAZZA, GARY A2026–2026name in abstract: daraxonrasib
R21CA309360Identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic cancerUNIV OF NORTH CAROLINA CHAPEL HILLMILNER, JOHN JUSTIN2026–2026name in abstract: RMC-6236
UG3CA311486Novel pan-RAS Inhibitors from Natural Products: A Safer Approach for Colorectal Cancer InterceptionAUBURN UNIVERSITY AT AUBURNPIAZZA, GARY A2026–2026name in project terms: daraxonrasib
R21CA297690Noncovalent interaction of mutant KRAS inhibitorsDUKE UNIVERSITYCHI, JEN-TSAN ASHLEY2025–2025name in abstract: RMC-6236

Notes

Multi-selective RAS(ON) tri-complex inhibitor. FDA approved 2026-08-26 as Rasonque (pancreatic cancer).

How to cite

daraxonrasib (AXP000027.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000027.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.